It’s time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
Sometimes a spec stock turns out to be more right than even Cramer imagined.
NPS Pharmaceuticals is a developer of orphan drugs for ultra-rare diseases, and its stock has been on a tear for 6 months. Its CEO Dr. Francois Nader discusses its latest trials and FDA approvals.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
"It's speculative, but I think we could have a real opportunity here," said Cramer
NPS Pharmaceuticals CEO Dr. Francois Nader discusses the approval of its short bowel syndrome drug Gattex, and what's next for the company.
TheStreet.com offers up 13 biotech predictions for 2013.
NPS Pharmaceuticals president & CEO Dr. Francois Nader, discusses strategies his company uses to finding value for shareholders, and appealing to the FDA.
NEW YORK-- A Food and Drug Administration advisory panel on Tuesday recommended that the FDA approve NPS Pharmaceuticals Inc.' s experimental bowel drug Gattex. The positive recommendation from the Gastrointestinal Drugs Advisory Committee makes it more likely the FDA will approve Gattex, although does not guarantee approval.
NEW YORK-- Trading of NPS Pharmaceuticals Inc. shares was halted Tuesday as a Food and Drug Administration advisory panel began discussing NPS' experimental bowel drug Gattex. NPS will discuss Gattex with the FDA's Gastrointestinal Drugs Advisory Committee. NPS Pharmaceuticals shares trade on the Nasdaq Global Market.
NEW YORK-- Shares of NPS Pharmaceuticals Inc. surged to their highest price in more than six years Friday as investors hope that a Food and Drug Administration advisory panel will recommend that the FDA approve NPS' bowel drug Gattex.
Oct 12- NPS Pharmaceuticals Inc:. *S&P Capital IQ cuts NPS Pharmaceuticals price target by $2 to $15;. Reuters Station users, click. 1568.
*FDA staff found 3 concerns, but safety restrictions not needed. "There was, on a consensus basis, a little apprehension about what the safety questions would be and these documents make it pretty clear that the FDA is not overly concerned or views these risks as significant," McNicoll, Lewis& Vlak analyst Ed Arce said.
Oct 12- U.S. drug reviewers found three serious concerns related to NPS Pharmaceuticals Inc's experimental drug for short bowel syndrome, but said they did not think the drug needed to be restricted for safety reasons, according to documents posted by the Food and Drug Administration on its website Friday.
NEW YORK, Oct 12- NPS Pharmaceuticals Inc:.
Oct 12- NPS Pharmaceuticals Inc:. *US FDA staff says observed 3 serious risks with NPS Pharmaceuticals'. teduglutide in short bowel syndrome program.
Oct 12- NPS Pharmaceuticals Inc:. *BMO raises NPS Pharmaceuticals Inc price target to $7 from $5;. Reuters Station users, click. 1568.
Oct 12- NPS Pharmaceuticals Inc:. *S&P Capital IQ raises NPS Pharmaceuticals price. Reuters Station users, click. 1568.
Check out which companies are making headlines after the bell Wednesday.
Take a look at some of Friday's midday movers:
From the mindless trivia department: The biggest ETF of all is the SPDR S&P 500 Index, with $93 billion in assets.